Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically suppressed HIV-1-infected adolescents

Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically suppressed HIV-1-infected adolescents

© 2018 International Medical Press. Background: Rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor drug, could be a favourable drug for maintenance therapy in HIV-infected adolescents because it has few long-term side effects. However, data among adolescents switching from efavirenz...

Full description

Saved in:

Bibliographic Details
Main Authors:	Watsamon Jantarabenjakul, Suvaporn Anugulruengkitt, Naruporn Kasipong, Narukjaporn Thammajaruk, Jiratchaya Sophonphan, Torsak Bunupuradah, Tim R. Cressey, Angela Colbers, David M. Burger, Wanatpreeya Phongsamart, Thanyawee Puthanakit, Chitsanu Pancharoen
Format:	Journal
Published:	2018
Subjects:	Medicine Pharmacology, Toxicology and Pharmaceutics
Online Access:	https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85051217524&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/59058
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	Chiang Mai University

Similar Items

Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically suppressed HIV-1-infected adolescents
by: Watsamon Jantarabenjakul, et al.
Published: (2019)

Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand
by: Wanatpreeya Phongsamart, et al.
Published: (2022)

Nevirapine Concentrations During the First Month of Life and Maternal Efavirenz Washout in High-Risk HIV-Exposed Infants Receiving Triple Antiretroviral Prophylaxis
by: Suvaporn Anugulruengkitt, et al.
Published: (2019)

Nevirapine concentrations during the first month of life and maternal efavirenz washout in high-risk hiv-exposed infants receiving triple antiretroviral prophylaxis
by: Suvaporn Anugulruengkitt, et al.
Published: (2020)

Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand
by: Phongsamart W.
Published: (2023)

Safety of 6-week Neonatal Triple-combination Antiretroviral Postexposure Prophylaxis in High-risk HIV-exposed Infants
by: Suvaporn Anugulruengkitt, et al.
Published: (2020)

Safety of 6-week Neonatal Triple-combination Antiretroviral Postexposure Prophylaxis in High-risk HIV-exposed Infants
by: Suvaporn Anugulruengkitt, et al.
Published: (2020)

Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children
by: Pakpoom Janewongwirot, et al.
Published: (2018)

Safety and effectiveness of switching to abacavir/lamivudine plus rilpivirine for maintenance therapy in virologically suppressed HIV-1 individuals in Singapore (SEALS)
by: Lim, Z. C., et al.
Published: (2021)

Safety and effectiveness of switching to Abacavir/Lamivudine plus rilpivirine for maintenance therapy in virologically suppressed HIV-1 individuals in Singapore (SEALS)
by: Lim, Z. C., et al.
Published: (2022)

Efavirenz pharmacokinetics during pregnancy and infant washout
by: Regis Kreitchmann, et al.
Published: (2019)

Predictors of late virologic failure after initial successful suppression of HIV replication on efavirenz-based antiretroviral therapy
by: Isaac Singini, et al.
Published: (2018)

Predictors of late virologic failure after initial successful suppression of HIV replication on efavirenz-based antiretroviral therapy
by: Singini I., et al.
Published: (2017)

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial
by: Molina J., et al.
Published: (2017)

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial
by: Jean Michel Molina, et al.
Published: (2018)

Efficacy of rilpivirine-based regimens as switch therapy from nevirapine-based regimens in human immunodeficiency virus-infected patients with virological suppression: A randomized controlled trial
by: Porkaew Petchkum, et al.
Published: (2020)

Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: Comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir
by: Kulkanya Chokephaibulkit, et al.
Published: (2018)

Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: Comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir
by: Kulkanya Chokephaibulkit, et al.
Published: (2018)

Impact of tenofovir disoproxil fumarate on bone metabolism and bone mass among perinatally HIV-infected Asian adolescents
by: Tavitiya Sudjaritruk, et al.
Published: (2018)

Impact of tenofovir disoproxil fumarate on bone metabolism and bone mass among perinatally HIV-infected Asian adolescents
by: Tavitiya Sudjaritruk, et al.
Published: (2018)

Pharmacological assessment of efavirenz weight-band dosing recommendations in HIV-infected thai children
by: Tim R. Cressey, et al.
Published: (2018)

Pharmacological assessment of efavirenz weight-band dosing recommendations in HIV-infected thai children
by: Tim R. Cressey, et al.
Published: (2018)

Pharmacological assessment of efavirenz weight-band dosing recommendations in HIV-infected thai children
by: Tim R. Cressey, et al.
Published: (2018)

Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women
by: Anna H. Tran, et al.
Published: (2018)

Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women
by: Tran A., et al.
Published: (2017)

Pharmacokinetics of Atazanavir/ritonavir among HIV-infected Thai children concomitantly taking tenofovir disoproxil fumarate
by: Torsak Bunupuradah, et al.
Published: (2018)

Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials
by: Calvin J. Cohen, et al.
Published: (2018)

Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials
by: Cohen C., et al.
Published: (2017)

Hypovitaminosis D and hyperparathyroidism: Effects on bone turnover and bone mineral density among perinatally HIV-infected adolescents
by: Tavitiya Sudjaritruk, et al.
Published: (2018)

Early and Late Virologic Failure After Virologic Suppression in HIV-Infected Asian Children and Adolescents
by: Weiwei Mu, et al.
Published: (2019)

Early and Late Virologic Failure after Virologic Suppression in HIV-Infected Asian Children and Adolescents
by: Weiwei Mu, et al.
Published: (2020)

Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO)
by: David A. Wohl, et al.
Published: (2018)

Antimicrobial prescription patterns in a tertiary-care pediatric unit in Thailand
by: Sineenart Chautrakarn, et al.
Published: (2020)

Immunogenicity and Reactogenicity of mRNA BNT162b2 COVID-19 Vaccine among Thai Adolescents with Chronic Diseases
by: Napaporn Chantasrisawad, et al.
Published: (2022)

Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing
by: Linda Aurpibul, et al.
Published: (2018)

Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing
by: Linda Aurpibul, et al.
Published: (2018)

Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing
by: Linda Aurpibul, et al.
Published: (2018)

Virological and immunological responses of efavirenz-based HAART regimen initiated in HIV-infected patients at CD4 < 100 versus CD4 ≥ 100 cells/mm 3
by: Sasisopin Kiertiburanakul, et al.
Published: (2018)

Etravirine and rilpivirine resistance in HIV-1 subtype CRF01-AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens
by: Torsak Bunupuradah, et al.
Published: (2018)

Influence of CYP3A5 and SLCO1B1 polymorphisms on atazanavir/r concentrations in Thai HIV-infected patients
by: Noppaket Singkham, et al.
Published: (2019)